** Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O rise 1.8% to $3.42 premarket

** Company says it is reducing headcount by about 30% and its 12-month cash burn by nearly 25%

** Adds it is restructuring its drug development program to focus on its cardiovascular therapies and its main gene therapy candidate, kresladi, being developed for the treatment of a rare immunodeficiency disorder called severe leukocyte adhesion deficiency

** Up to last close, stock down 73.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))